cetuximab + cisplatin + capecitabine

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting its activation and downstream signaling, which leads to inhibition of cell proliferation, survival, and tumor progression. It is primarily used in the treatment of colorectal cancer and squamous cell carcinoma of the head and neck[1][3][4]. Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells; it is widely used for various solid tumors including head and neck, lung, ovarian, bladder, and testicular cancers. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU) in vivo; it inhibits thymidylate synthase resulting in impaired DNA synthesis. Capecitabine is indicated for breast cancer, gastric cancer, colorectal cancer (including adjuvant therapy), among others[6]. The combination of these agents may be used as part of chemoradiotherapy regimens for certain advanced or metastatic cancers.

Brand names

ErbituxXeloda

Other names

cetuximab, cisplatin, capecitabineErbitux + cisplatin + Xeloda